Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study
July 26, 2021 02:00 ET | Immunicum AB
Press Release 26 July 2021 Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study  -- Independent Data Safety and Monitoring Board (DSMB) issues...
Immunicum tillkännager positiv granskning från Data Safety Monitoring Board av fas Ib IILIAD-studien
July 26, 2021 02:00 ET | Immunicum AB
Press Release 26 July 2021  Immunicum tillkännager positiv granskning från Data Safety Monitoring Board av fas Ib IILIAD-studien -- Independent Data Safety and Monitoring Board (DSMB) har avgivit...
HIV Cure Program Releases Initial Clinical Trial Data
July 15, 2021 23:51 ET | American Gene Technologies
ROCKVILLE, Md., July 15, 2021 (GLOBE NEWSWIRE) -- American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
May 27, 2021 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 27, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
February 08, 2021 07:05 ET | uniQure Inc.
~ No Significant Safety Concerns Observed ~ ~ Independent Data Safety Monitoring Board Recommends Proceeding with Study Enrollment ~ ~ Full Enrollment of First Cohort Expected Mid-2021 ~ LEXINGTON,...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator
November 15, 2020 19:35 ET | BioAegis Therapeutics
No drug-related safety signals identified by the independent Data and Safety Monitoring Board.MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage,...
Logo.jpg
Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer
May 29, 2020 08:30 ET | Celsion CORP
 Excellent Surgical Response Noted at the Higher, 100 mg/m2 Dose  Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month...
Logo.jpg
Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m² in 15 Randomized Patients with Advanced Ovarian Cancer
February 06, 2020 09:25 ET | Celsion CORP
 Phase 2 Portion Will Continue After Patients Have Completed Their Full Treatment Regimen of up to 17 doses of GEN-1 plus Standard Chemotherapy LAWRENCEVILLE, N.J., Feb. 06, 2020 (GLOBE...
hemostemix-logo-small.jpg
Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract
October 21, 2019 08:30 ET | Hemostemix Inc.
CALGARY, Alberta, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces Positive DSMB Recommendation to Continue Phase 3 Pivotal CardiAMP Heart Failure Study as Planned
September 16, 2019 08:00 ET | BioCardia, Inc.
SAN CARLOS, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced...